---
title: "Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Study 219239 relative bioavailability of vial and prefilled syringe"
description: "Formulary evidence on Hibsago (bepirovirsen, GSK3228836) in Chronic hepatitis B virus infection in adults without cirrhosis: Study 219239 relative bioavailability of vial and prefilled syringe. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 30 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence/study-219239-relative-bioavailability-of-vial-and-prefilled-syringe"
published: "2026-10-21T22:39:04-04:00"
modified: "2026-10-22T19:07:03-04:00"
---

# Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Study 219239 relative bioavailability of vial and prefilled syringe

<a id="heading-3.1.14"></a>

## 3.1.14 Study 219239 Relative Bioavailability of Vial and Prefilled Syringe

<a id="heading-3.1.14.1"></a>

### 3.1.14.1 Objective

<a id="topic-3.1.14.1-1"></a>

#### Aim stated in the registry record

> “The aim of this study is to provide relative bioavailability data to support the transition from the vial presentation of bepirovirsen, to a ready-to-use liquid in a PFS SSD when both are given by a health care professional. The study will also assess self-administration using the PFS SDD, and the safety and tolerability of bepirovirsen.”

Source: [ClinicalTrials.gov NCT06058390](https://clinicaltrials.gov/study/NCT06058390)

<a id="topic-3.1.14.1-2"></a>

#### Aim stated in the publication

> “The current study was designed to evaluate the relative bioavailability of bepirovirsen when delivered via SC injection from a vial (HCP‐administered) or by a PFS SSD (HCP‐ or self‐administered) in healthy adult participants. Safety and tolerability were assessed as a secondary objective.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="heading-3.1.14.2"></a>

### 3.1.14.2 Location and Study Date

<a id="topic-3.1.14.2-1"></a>

#### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start (actual) | “2023-10-04” |
| Primary completion (actual) | “2024-05-03” |
| Study completion (actual) | “2024-05-03” |
| Results first posted | “2025-07-18” |
| Other study identifiers | “219239” |

Source: [ClinicalTrials.gov NCT06058390](https://clinicaltrials.gov/study/NCT06058390)

<a id="topic-3.1.14.2-2"></a>

#### Study locations in the registry record

> “This study has 2 locations”
> “Las Vegas, Nevada, United States, 89113”
> “Austin, Texas, United States, 78744”

Source: [ClinicalTrials.gov NCT06058390](https://clinicaltrials.gov/study/NCT06058390)

<a id="heading-3.1.14.3"></a>

### 3.1.14.3 Study Design

<a id="topic-3.1.14.3-1"></a>

#### Randomized, open-label, parallel-group design with stratification

> “This was a Phase 1, open‐label, randomized, parallel‐group study (219239, NCT06058390). Participants were randomized 3:3:2:2 to receive a single dose of bepirovirsen 300 mg either administered by a HCP from a vial (Group 1), administered by a HCP using the PFS SSD (Group 2), self‐administered using the PFS SSD with training from a HCP (Group 3), or self‐administered using the PFS SSD without training from a HCP (Group 4) (Figure 1).”
> “The randomization was stratified by body weight (50‐<70 kg, 70‐<80 kg, and ≥80 kg). The site of injection was randomized in a 1:1:1 ratio to the upper arm, abdomen, or thigh in Groups 1 and 2, and in a 1:1 ratio to abdomen or thigh in Groups 3 and 4.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.3-2"></a>

#### Pharmacokinetic sampling schedule

> “Pharmacokinetic (PK) samples were collected from all participants pre‐dose and at 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 168, 336, 672, 1008, and 1512 h post‐dose.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.3-3"></a>

#### Healthy participants as the study population

> “Conducting the study in healthy participants mitigates the recruitment and patient burden limitations with administering a single dose of bepirovirsen to CHB patients.”

Source: [GSK 219239 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/90/NCT06058390/Prot_000.pdf)

<a id="heading-3.1.14.4"></a>

### 3.1.14.4 Eligibility Criteria

<a id="topic-3.1.14.4-1"></a>

#### Inclusion and exclusion criteria in the publication

> “Healthy male and female participants, aged between 18 and 55 years, were enrolled from 2 centers in the United States. Participants were required to have body weight ≥50 kg and body mass index (BMI) within 19‐29.9 kg/m2.”
> “Participants were excluded if they had: a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; or any malignancy within the past 5 years; platelets <140×109/L; alanine aminotransferase (ALT) >1.5× upper limit of normal (ULN), or total bilirubin >1.5×ULN; a current or chronic history of liver disease or known hepatic or biliary abnormalities; or prior treatment with any oligonucleotide or siRNA within 12 months before dosing.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="heading-3.1.14.5"></a>

### 3.1.14.5 Treatment

<a id="topic-3.1.14.5-1"></a>

#### Single 300 mg dose given as two 150 mg injections

> “All participants received a single dose of bepirovirsen 300 mg either by vial or PFS SSD, given as two 150 mg SC injections that were given as close together in time as possible (within 5 min) and spaced at least 5 cm apart.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.5-2"></a>

#### Prefilled syringe with safety syringe device

> “The bepirovirsen PFS SSD consisted of a sterile liquid drug product in a single‐use clear glass PFS assembled into an SSD that delivered 1 mL of 150 mg/mL bepirovirsen for SC administration.”
> “The formulation of bepirovirsen is identical between the vial and the PFS SSD.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="heading-3.1.14.6"></a>

### 3.1.14.6 Study Outcomes

<a id="heading-3.1.14.6.1"></a>

#### 3.1.14.6.1 Rationale for Using Relative Bioavailability (Plasma Cmax and AUC) as the Primary Endpoint

<a id="topic-3.1.14.6.1-1"></a>

##### Primary and secondary endpoints and the bioequivalence criterion

> “The primary endpoint was to estimate the relative bioavailability of a single dose of bepirovirsen delivered by SC injection by a HCP in healthy participants using a vial versus PFS SSD.”
> “Bepirovirsen exposure was considered to be bioequivalent if the 90% CIs for the GMRs of both Cmax and AUC(0‐inf) fell within the standard bioequivalence reference range of 0.80 to 1.25.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.6.1-2"></a>

##### Purpose of the bioavailability comparison

> “The aim of this study is to provide relative bioavailability data to support the transition from the vial presentation of bepirovirsen, which is currently under investigation in the Phase 3 trials, to a ready-to-use liquid in a PFS fitted with an SSD.”

Source: [GSK 219239 protocol (2023)](https://cdn.clinicaltrials.gov/large-docs/90/NCT06058390/Prot_000.pdf)

<a id="heading-3.1.14.7"></a>

### 3.1.14.7 Statistical Analysis Description

<a id="heading-3.1.14.7.1"></a>

#### 3.1.14.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.14.7.1-1"></a>

##### Participants screened, enrolled, and analyzed

> “A total of 359 participants were screened and 160 participants enrolled in the study.”
> “The latter participant was not included in the analysis, leading to a total study analysis population of 159 participants (Group 1, n = 46; Group 2, n = 49; Group 3, n = 32; Group 4, n = 32).”
> “A total of 153 of the 159 study analysis participants were included in the PK summaries and statistical comparisons of the PK data for the primary and secondary endpoint analyses.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.7.1-2"></a>

##### Planned sample size

> “The planned sample size was 160 participants.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="heading-3.1.14.7.2"></a>

#### 3.1.14.7.2 Description of Analysis Sets

<a id="topic-3.1.14.7.2-1"></a>

##### Analysis sets in the registry results

> “All-cause mortality, SAEs and non-SAEs were reported for Safety Population which included participants who received study intervention. One participant from Enrolled Population (N=160) did not receive study intervention, hence was not included in Safety Population (N=159).”
> “Pharmacokinetic (PK) Parameter Population included all participants in the PK concentration Population for whom valid and evaluable plasma PK parameters were derived.”

Source: [ClinicalTrials.gov NCT06058390](https://clinicaltrials.gov/study/NCT06058390?tab=results)

<a id="topic-3.1.14.7.2-2"></a>

##### Statistical model for relative bioavailability

> “For each of the primary and secondary endpoints, data were analyzed using separate linear fixed effects models with randomized group (i.e. Group 1 versus Group 2 for the primary analysis; Group 2 versus Group 3, and Group 2 versus Group 4 for the secondary analyses) and injection site (arm, abdomen, or thigh for Groups 1 and 2, and abdomen or thigh for Groups 3 and 4) included as categorical covariates, and natural logarithm transformed baseline weight as a continuous covariate.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="heading-3.1.14.8"></a>

### 3.1.14.8 Results

<a id="heading-3.1.14.8.1"></a>

#### 3.1.14.8.1 Participant Disposition

<a id="topic-3.1.14.8.1-1"></a>

##### Participant flow in the registry results

| Milestone | Vial by HCP | PFS SSD by HCP | PFS SSD self-administered after training | PFS SSD self-administered without training |
| --- | --- | --- | --- | --- |
| Started | “46” | “49” | “32” | “33” |
| Completed | “46” | “49” | “30” | “30” |
| Not completed | “0” | “0” | “2” | “3” |

Source: [ClinicalTrials.gov NCT06058390](https://clinicaltrials.gov/study/NCT06058390?tab=results)

<a id="topic-3.1.14.8.1-2"></a>

##### Withdrawals and incomplete doses

> “In total, 5 participants across Groups 3 and 4 withdrew from the study, of whom 1 participant (Group 4) was withdrawn due to physician decision (based on failure to cooperate and complete outpatient visits), 3 participants (2 in Group 3 and 1 in Group 4) were lost to follow‐up, and 1 participant (Group 4) did not remove the cap from the PFS SSD during dosing and did not receive any study intervention.”
> “There were 6 participants (3 in Group 3 and 3 in Group 4) who each received an incomplete dose (of either the first or second dose or both) of study intervention due to incorrect use of the PFS and were excluded from the PK analyses (Table S3).”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="heading-3.1.14.8.2"></a>

#### 3.1.14.8.2 Baseline Characteristics

<a id="topic-3.1.14.8.2-1"></a>

##### Demographics of the analysis population

> “In the overall study population, 52% of participants were female, the mean (SD) age was 36.5 (9.35) years, and the mean (SD) BMI was 25.68 (2.746) kg/m2. The majority of participants were of White (48%) or Black/African American (35%) race and were not of Hispanic/Latino ethnicity (67%). Most of the participants were in the 50 to <70 kg (39%) and 70 to <80 kg (36%) weight categories, with similar distribution between weight categories across all 4 treatment groups.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="heading-3.1.14.8.3"></a>

#### 3.1.14.8.3 Efficacy Results

<a id="topic-3.1.14.8.3-1"></a>

##### Primary endpoint: vial versus PFS SSD given by a healthcare professional

> “Analysis of the primary endpoint demonstrated the bioequivalence of bepirovirsen exposure from a vial versus PFS SSD when HCP‐administered, as the GMR (90% CI) was 1.02 (0.91, 1.14) for Cmax and 1.05 (0.96, 1.15) for AUC(0‐inf) (Table 3).”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.8.3-2"></a>

##### Secondary endpoints: self-administration with and without training

> “The GMR (90% CI) with participant training (Group 2 versus Group 3) was 1.02 (0.88, 1.18) for Cmax and 0.98 (0.88, 1.09) for AUC(0‐inf), and without participant training (Group 2 versus Group 4) was 0.99 (0.87, 1.13) for Cmax and 0.97 (0.87, 1.08) for AUC(0‐inf).”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.8.3-3"></a>

##### Plasma PK parameters by group (geometric mean, % CV)

| Parameter | Vial by HCP (N = 46) | PFS SSD by HCP (N = 49) | PFS SSD self-administered with training (N = 29) | PFS SSD self-administered without training (N = 29) |
| --- | --- | --- | --- | --- |
| Cmax (ng/mL) | “9873.38 (40.96)” | “10,242.48 (39.54)” | “10,391.83 (42.70)” | “9516.35 (47.41)” |
| AUC(0‐inf) (ng·h/mL) | “111,843.70 (32.93)” | “119,271.61 (29.70)” | “119,080.46 (26.28)” | “112,338.58 (35.01)” |

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.8.3-4"></a>

##### Effect of body weight and injection site

> “Between the 50‐<70kg and ≥80kg groups, there was a decrease of 24%‐47% in geometric mean Cmax and a decrease of 19%‐43% in geometric mean AUC(0‐inf).”
> “Across all treatment groups the geometric mean Cmax of bepirovirsen tended to be lower when administered in the thigh compared with the other injection sites.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.8.3-5"></a>

##### Registry results: 90% confidence intervals for the primary comparison

> “0.91 to 1.14”
> “0.96 to 1.15”

Source: [ClinicalTrials.gov NCT06058390](https://clinicaltrials.gov/study/NCT06058390?tab=results)

<a id="heading-3.1.14.8.4"></a>

#### 3.1.14.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.14.8.5"></a>

#### 3.1.14.8.5 Safety Results

<a id="topic-3.1.14.8.5-1"></a>

##### Overall adverse events

> “A total of 94% (150/159) of participants reported AEs, with similar proportions of participants reporting AEs across all treatment groups (88‐100%; Table 5 and Table S4). Most AEs were considered related to study drug by the investigator (148/159 participants [93%]; Table S5). There were no serious or fatal AEs. Most AEs were Grade 1/2 in severity; <10% of participants reported Grade 3 AEs, and no Grade 4, Grade 5, or unknown Grade AEs were reported.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.8.5-2"></a>

##### Adverse events reported in at least 3% of participants overall

| Preferred term | Vial by HCP (N = 46) | PFS SSD by HCP (N = 49) | PFS SSD self-administered with training (N = 32) | PFS SSD self-administered without training (N = 32) | Total (N = 159) |
| --- | --- | --- | --- | --- | --- |
| Any event | “45 (98%)” | “43 (88%)” | “32 (100%)” | “30 (94%)” | “150 (94%)” |
| Injection site erythema | “35 (76%)” | “37 (76%)” | “30 (94%)” | “30 (94%)” | “132 (83%)” |
| Injection site swelling | “21 (46%)” | “24 (49%)” | “14 (44%)” | “19 (59%)” | “78 (49%)” |
| Injection site pain | “23 (50%)” | “22 (45%)” | “10 (31%)” | “12 (38%)” | “67 (42%)” |
| Injection site pruritus | “8 (17%)” | “11 (22%)” | “9 (28%)” | “13 (41%)” | “41 (26%)” |
| Headache | “12 (26%)” | “5 (10%)” | “5 (16%)” | “7 (22%)” | “29 (18%)” |
| Nausea | “3 (7%)” | “3 (6%)” | “2 (6%)” | “1 (3%)” | “9 (6%)” |
| Myalgia | “5 (11%)” | “1 (2%)” | “1 (3%)” | “1 (3%)” | “8 (5%)” |
| Pyrexia | “3 (7%)” | “2 (4%)” | “1 (3%)” | “1 (3%)” | “7 (4%)” |

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.8.5-3"></a>

##### Adverse events of special interest: injection site reactions, thrombocytopenia, and ALT increases

> “The proportion of participants experiencing injection site reactions was higher when PFS SSD was self‐administered (Group 3: 32/32 [100%], Group 4: 30/32 [94%]) compared with HCP administration (Group 2: 43/49 [88%]).”
> “AESIs related to thrombocytopenia were reported by 18% (29/159) of participants with no clear difference between treatment groups”
> “Both ALT increases were <5× ULN. One participant in the self‐administered PFS SSD without training group reported a Grade 3 platelet decline to <100×109/L. This occurred 65 days after study‐dose administration, the participant was asymptomatic and had no clinical bleeding.”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.8.5-4"></a>

##### Deaths, serious adverse events, and thrombocytopenia in the registry results

| Event | Vial by HCP | PFS SSD by HCP | PFS SSD self-administered after training | PFS SSD self-administered without training |
| --- | --- | --- | --- | --- |
| All-cause mortality | “0/46 (0.00%)” | “0/49 (0.00%)” | “0/32 (0.00%)” | “0/32 (0.00%)” |
| Serious adverse events | “0/46 (0.00%)” | “0/49 (0.00%)” | “0/32 (0.00%)” | “0/32 (0.00%)” |
| Thrombocytopenia | “1/46 (2.17%)” | “0/49 (0.00%)” | “0/32 (0.00%)” | “2/32 (6.25%)” |

Source: [ClinicalTrials.gov NCT06058390](https://clinicaltrials.gov/study/NCT06058390?tab=results)

<a id="heading-3.1.14.9"></a>

### 3.1.14.9 Study Limitations

<a id="topic-3.1.14.9-1"></a>

#### Summary: study limitations

Study 219239 compared a single 300 mg dose in 159 healthy participants aged 18 to 55 years, so it provides no information on repeated dosing over the 24-week course or on device use by patients with chronic hepatitis B. Six participants in the self-administration groups (3 in Group 3 and 3 in Group 4, each of 32 participants) received an incomplete dose because of incorrect use of the prefilled syringe and were excluded from the PK analyses, and injection site reactions occurred in 100% and 94% of the self-administration groups compared with 88% with healthcare professional administration. Exposure was lower in the thigh and decreased with increasing body weight, and the authors state that it is unclear whether the injection-site difference is real or due to variability.

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

<a id="topic-3.1.14.9-2"></a>

#### Limitations stated by the investigators

> “However, the use of healthy participants may also be considered a limitation because this is not the intended population for bepirovirsen; this is a common approach for relative bioavailability studies, owing to the difficulty of enrolling patients in a single‐dose study.”
> “It is unclear from the data whether the difference in exposure by injection site is real or due to variability.”
> “While 6 participants received an incomplete dose of bepirovirsen, owing to incorrect use of the PFS (4 of them injected approximately 75% to 95% of the dose), device usability was evaluated in separate formative and summative human factors studies, and the device and instructions for use were successfully validated for self‐administration (unpublished data).”

Source: [Youssef et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12856967/)

## Related pages
- [Hibsago (bepirovirsen): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Terms and abbreviations](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/terms-and-abbreviations.md)
- [Hibsago (bepirovirsen): Chronic hepatitis B virus infection in adults without cirrhosis](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/executive-summary.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Product information and disease description](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/product-information-and-disease-description.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Clinical evidence](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/clinical-evidence.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: Economic information and modeling report](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/economics) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/economics.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: References](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/references) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/references.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: new drug review](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/monograph/review) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/monograph/review.md)
- [Hibsago (bepirovirsen) in Chronic hepatitis B virus infection in adults without cirrhosis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/hibsago--chronic-hepatitis-b-virus-infection-in-adults-without-cirrhosis/cost-effectiveness-analyses.md)